<DOC>
	<DOCNO>NCT01377831</DOCNO>
	<brief_summary>To determine rate extent absorption racemic ketamine sublingual wafer</brief_summary>
	<brief_title>Study Ketamine Administered Intravenously Sublingual Wafer</brief_title>
	<detailed_description>1 . To determine apparent rate disintegration sublingual wafer 2 . To determine overall clinical tolerability ketamine administer single dose via sublingual route . Tolerability assess use range objective subjective parameter assess use modify Likert Bond Lader scale .</detailed_description>
	<mesh_term>Ketamine</mesh_term>
	<criteria>1 . Adult male age 1865 year . 2 . Good general health without clinically significant renal , hepatic , cardiac respiratory disease , determine Principal Investigator . 3 . Good general mental health determine score Symptom Checklist90R ( SCL90R® ) , screen instrument evaluate broad range psychological problem symptom psychopathology . 4 . Agree capable signing Informed Consent Form . 5 . Have suitable venous access blood sampling . 6 . BMI within range 1930 kg/m2 . 1 . Renal impairment evidence estimate creatinine clearance ( CrCl ) , measure CockcroftGault method , less 90 mL/min . 2 . Have laboratory value Screening Visit outside normal range , unless judge Investigator clinically significant appropriate evaluation . 3 . A score two standard deviation mean key nine scale SCL90R ® 4 . Any medical condition opinion Investigator may adversely impact participant 's ability complete study , include limited : History cerebral trauma stroke History seizure epilepsy Hyperthyroidism Recent clinically significant URTI ( within two week Day 1 ) respiratory infection History Myocardial Infarction clinically significant cardiac disease include cardiac arrhythmia . Poorly control hypertension assess Principal Investigator . Clinically significant history asthma require regular supportive preventative therapy ( childhood asthma resolve &gt; 5 year previously may suitable inclusion discretion Investigator . Glaucoma 5 . Plasma AST , ALT ALP test excess 1.5 time upper limit normal . 6 . History severe allergic anaphylactic drugrelated reaction . 7 . History hypersensitivity ketamine excipients . 8 . Current ( within last six month ) clinically significant psychiatric disorder include anxiety , psychosis depression . 9 . Concurrent use medication regular daily basis include limited , theophylline , benzodiazepine , thyroxine , sedatives antianxiolytics . 10 . Participation another clinical trial investigational agent within 30 day study entry . 11 . Known history past present infection hepatitis C virus ( HCV ) , hepatitis B human immunodeficiency virus ( HIV ) . 12 . Clinically significant abnormal ECG ( 12lead ) screen visit prior dose Day 1 , determine Investigator . 13 . Participants mark prolongation QT correct ( QTc ) interval ( i.e. , repeat demonstration QTc &gt; 430 msec male ) screen prior dose Day 1 either study period allow continue study . 14 . Significant history illicit drug alcohol use abuse ( determine Principal Investigator ) . 15 . Any alcohol use within 24 hour prior dose Day 1 study period . 16 . Unwillingness inability comply requirement protocol , include presence condition ( physical , mental , social ) likely affect participant return followup visit schedule . 17 . Blood donation ( 1 unit ) within 1 month prior screen visit . 18 . Current previous tobacco user ( within 12 month prior Day 1 ) . 19 . Planned surgical procedure require general anaesthesia study period within two week study completion</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>